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Summary This study combines secondary analysis of efficacy and side-effect data from a randomised
controlled trial with estimates of resource use to evaluate the likely economic effects of the new antiemetic
agent ondansetron. Costs, effects and cost-effectiveness of ondansetron in the prophylaxis of acute nausea and
vomiting induced by chemotherapy are assessed relative to antiemetic therapy with metoclopramide. Superior
efficacy of ondansetron is quantified both in terms of significant emesis avoided and emesis management costs
avoided. A simple cost analysis, with the metoclopramide dosage priced at £10, indicates that therapy with
ondansetron would give equivalent net treatment costs, at a price ratio (ondansetron/metoclopramide) of 2.3
to 1. If therapeutic success is defined as the avoidance of emesis and antiemetic side-effects, then the two
therapies would be equally cost-effective at a drug price ratio of 5 to 1. We conclude that, (i) economic
evaluation prior to price setting is feasible and informative; (ii) such models can indicate prospective data
collection priorities.
It is now widely accepted that the economic implications of
new therapies need to be considered and that health care
systems need to ensure that the scarce resources available to
them are used effectively and efficiently. An increasing
number of economic evaluations of health care interventions
have been published, including studies relating to phar-
maceutical products in general (e.g. Oster & Epstein, 1987;
O'Brien et al., 1990; Buxton et al., 1991) and to the screening
and treatment of cancer in particular (Levine et al., 1985;
Hillner & Smith, 1991).
The typical context of economic evaluation for a new
pharmaceutical is when the product has been both approved
by regulatory authorities (i.e. demonstrated safety and
efficacy) and marketed at a particular price. In contrast to
this post-marketing assessment, it is possible to undertake
pre-marketing economic evaluation where the price of the
new product has not yet been set, but data exist on other
aspects of treatment costs and effects. An obvious use of such
pre-marketing data is as an input into the process of deter-
mining appropriate pricing or reimbursement levels for the
new drug, recognising that its cost-effectiveness, relative to
the best alternative therapy is, in part, a function of its price.
This paper presents an example of a simple pre-marketing
economic evaluation of the antiemetic ondansetron. The
study combines secondary analysis of data from a large
randomised trial with estimates of emesis management costs
to determine the costs, effects and cost-effectiveness of
ondansetron relative to metoclopramide in the prophylaxis of
chemotherapy-induced emesis. These data are used to explore
the relationship between the costs and cost-effectiveness of
ondansetron and its price relative to metoclopramide.
Materials and methods
Available data on effects and side-effects
Data were available from a multicentre double-blind cross-
over study by Marty et al. (1990) which compared the
efficacy and safety of ondansetron versus metoclopramide in
the prophylaxis of acute nausea and vomiting induced by
cancer chemotherapy regimens containing cisplatin. The trial
was a randomised crossover design with two treatment
periods separated by a 3-4 week interval. Ondansetron was
given intravenously in a loading dose (8 mg) before cisplatin
administration and then in a continuous infusion (1 mg per
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hour) for 24 h. Metoclopramide was given intravenously in a
loading dose (3 mg kg-' body weight) before cisplatin and
infused (0.5 mg kg' per hour) for 8 h; placebo was infused
for the next 16 h. Cisplatin (80 to 100 mg per square metre)
was given over a one-hour period, 30 min after the loading
dose of the antiemetic.
Patients were of both sexes, hospitalised, aged 29-69, and
had cancers with a variety of primary tumour sites. An
interim analysis indicated superior efficacy of ondansetron
and the trial was stopped early: a total of 76 patients who
had received both drugs were available for analysis. The
main measure of outcome was the frequency of emetic
episodes (vomits plus wretches) in the first 24 h. As indicated
in Table I, 57 of 76 treatments (75%) with ondansetron
resulted in complete (no episodes) or nearly complete (one or
two episodes) control of emesis compared to 32 of 76
treatments (42%) with metoclopramide, a difference that was
statistically significant (P<0.001). The incidence of adverse
effects such as headache, sedation and diarrhoea was low and
similar in both therapy groups.
Constructing a probability tree
Original patient-specific data from the trial were re-analysed
for the purpose of constructing a simple probability tree for
each therapy group: a diagram combining clinical and treat-
ment events with their observed frequency of occurrence in
the trial. Such schematic structuring of clinical problems is
common in the literature of clinical decision analysis (Wein-
stein & Fineberg, 1980).
Table I Control of emesis in 76 patients by ondansetron and
metoclopramide
Emetic Number of treatments (per cent)
Control Ondansetron Metoclopramide
Complete
(no episodes) 35 (46) 12 (16)
Nearly complete
(1 or 2 episodes) 22 (29) 20 (26)
Partial
(3 - 5 episodes) 8 (11) 16 (21)
None
(>5 episodes) 11 (14) 28 (37)
Source: Marty, M. et al. (1990).
Note: Thus treatment with ondansetron results in complete or
nearly complete control of emesis in 57/76 (75%) of
treatments and hence in Figure 1 the probability of no
significant emesis is 0.75.
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The probability trees for ondansetron and metoclopramide
are presented in Figure 1. These diagrams indicate the four
criteria for partitioning each therapy data set are:
(i) the probability of suffering significant emesis
(defined as greater than two episodes within 24 h);
(ii) the probability of suffering at least one significant
antiemetic side-effect (includes all side-effects other
than those rated as mild/minor effects by inves-
tigators);
(iii) the probability of this side-effect being treated (i.e.
the proportion treated in the trial);
(iv) the probability that the side-effect is resolved (with
or without treatment).
Applying these criteria partitions each antiemetic therapy
group into ten mutually exclusive sub-groups corresponding
to the branch endpoints of the trees, El to EIO. Moving
from left to right on each tree the total of 76 patients are
progressively subdivided at each chance node (represented by
circles). For example, on the ondansetron tree the endpoint
E4 represents the two patients who experienced significant
emesis, a significant side-effect which was not treated but did
resolve. Therefore, based on this trial, there is a probability
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(0.58) SIGNIFICANT 10.78) RESOLVED(0.6) TREATED
EMESIS
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(0) UNRESOLVED(0.88) NO SIGNIFICANT SIDE EFFECTS
NO~~~~~~~O
SINOFCN (1.0) RESOLVED
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of 0.026 (2/76) that a patient will follow this course. Con-
versely it can be seen that the most probable outcome (pro-
bability = 0.67) is that a patient will experience no significant
emesis or side-effect with ondansetron (endpoint E6).
Economic evaluation methods
The differential costs of managing chemotherapy-induced
emesis with either ondansetron or metoclopramide are of two
sorts: (i) costs which all patients incur such as the cost of the
antiemetic drug itself; (ii) cost which occur for some but not
all patients (i.e. are probabilistic). These latter costs are due
to two general types of event: (i) response to individual
emetic episodes; (ii) response (which may include additional
prescribed therapy) to side-effects from antiemetic therapy.
Based on the regimens described in Gralla et al. (1987), the
ex-manufacturer price for the metoclopramide-based course
in this study is approximately £10. At this time no empirical
data exist on the costs of managing emetic episodes. In the
absence of reliable information, various cost assumptions
have been made based, in part, on good nursing practice
guidelines for emesis management (see Note 1). Explicit cost
Pathway:
N of
Pts
29
7
2
6
0
28
2
0
2
0
Prob Cost(£)
0.383 40
Expected
Cost (£)
15.32
0.092 65 5.99
0.026 65 1.69
0.079 60 4.74
0 60 0
0.370 10 3.7
0.025 35 0.88
0 35 0
0.025 30 0.76
0 30 0
76 34
14 0.185 40 7.4
2 0.026 65 1.67
1 0.013 65 0.85
2 0.026 60 1.56
0 0 60 0
51 0668 10 6.68
1 0.014 35 0.49
0 35
5 0.068 30 2.05
0 0 30 0
ONDANSETRON TOTAL 76 21
Figure 1 Probability trees for metoclopramide and ondansetron therapies. Seventy-six patients enter each therapy probability tree
and are subdivided at chance nodes (0). The probabilities of events at chance nodes are figures in brackets which always sum to
one.
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assumptions are detailed (see Note 2) and these suggest: (i) the
patient care cost of responding to significant emesis is approx-
imately £30; (ii) the patient care cost of responding to a
significant antiemetic side-effect is approximately £20; (iii) the
cost of treating an antiemetic side-effect is approximately £5.
By combining estimates of the various costs associated
with emesis and its management with incidence data
embodied in the probability trees it is possible to determine
the expected cost of emesis therapy for each group. Expected
costs are simply costs weighted by their probability of occur-
rence or incidence. Thus in the metoclopramide probability
tree a person reaching endpoint E4 will have incurred the
costs of metoclopramide (£10) + the costs of emesis
(£30) + the costs of side-effects (£20) = £60. However, the
trial data indicate that the probability of this experience for
any one patient receiving this drug is only 0.079 (six patients
out of 76) and hence the expected cost for this branch is
£4.74 (60 x 0.079). Summing the expected costs over all ten
endpoints gives the total expected cost for antiemetic therapy
with metoclopramide.
It should be noted that in the ondansetron tree, Figure 1,
the cost of ondansetron has initially been assumed equal to
metoclopramide (£10). Thus the observed difference in total
therapy cost is simply a function of the costs of emesis and
side-effect management.
There are various distinct forms of economic evaluation
available (Drummond et al., 1987). Two approaches were
appropriate here. The first was a simple cost analysis. A
threshold price for ondansetron was calculated at which price
the expected costs of the two therapy groups are equal. At
this price the extra cost of ondansetron itself, balances its
savings from the costs associated with its lower level of
emesis and side-effects.
The second method was cost-effectiveness analysis which
compares therapies in terms of their cost per unit of effect.
The expected costs for each therapy are defined as before.
Therapeutic success (effectiveness) is defined here in two
alternative ways: (i) as the number of patients with no
significant emesis; (ii) more restrictively, as the number of
patients with no significant emesis and no significant side
effects. For each definition of effectiveness the price of
ondansetron is found where the ratio of cost to effect for
metoclopramide and ondansetron are equal.
Results
Cost analysis
Define the expected costs of antiemetic therapy with
ondansetron, Co, and metoclopramide, Cm, as the sum of
antiemetic drug cost, C(d)0, C(d)m, (with ondansetron initially
assumed equal to metoclopramide at £10), and the costs of
emesis management, C(em)0, C(em)m, which vary according
to the differential probabilities of events and their associated
costs as detailed in Figure 1. Thus therapy costs can be
expressed in two simple equations:
CO= C(d)o + C(em) (=£10 + £L 1) from Figure 1 (1)
Cm = C(d)m + C(em)m (= £10 + £24) from Figure 1 (2)
Holding emesis management costs and metoclopramide costs
constant but allowing the price of ondansetron to vary, the
problem is to find the drug cost ratio, R*, (ondansetron/
metoclopramide), and implicitly the threshold cost of
ondansetron, C(d)0*, which equates treatment costs between
the two groups (Cm = C.). Rearranging equations 1 and 2:
C(d). + (C(em)m- C(em)o) C(d)(R* 2.3 (3)
C(d)m C(d)m
Thus the drug price ratio (R*) which equates total costs for
the two therapy groups is 2.3:1. Hence the use of ondanset-
ron would be cost reducing up to the point where it was
priced at 2.3 times that of metoclopramide at £10.
Cost-effectiveness
Using the same cost definitions, measures and notation, cost-
effectiveness analysis is used to calculate the ratios of cost to
effect (C/E) for the two therapy groups. Two alternative
measures of effectiveness or therapeutic success are analysed:
(i) with effectiveness defined as the number of patients, in
each therapy group who did not experience significant
emesis. Thus for ondansetron E. = 57 (of 76) patients and for
metoclopramide Em = 32 (of 76) patients. When drug prices
are equal (C(d). = C(d)m) then the ratio of cost per unit effect
is greater for metoclopramide. As before, the problem is to
find the drug price ratio, R* = C(d)o*/C(d)m which equates
the ratios of cost to effect for the two therapies. Algebraically
this can be expressed:
C(d),* + C(em)0 C(d)m + C(em)m
Eo' Em
and hence
co m
Eo Em
(4)
(5)
Substituting values into equation 4 and solving for the un-
known C(d).*, and hence R*, yields a price ratio (ondan-
setron/metoclopramide) of 5.0:1 which achieves the equality
in equation 5.
(ii) with effectiveness defined as the number of patients, in
each therapy group who do not experience significant emesis
and do not experience significant side-effects, for ondansetron
Eo = 51 (of 76) patients and for metoclopramide Em = 28 (of
76) patients. Performing the same calculations as in (i) the
price ratio which equalises the ratios of cost to effect is
marginally higher at 5.1.
These results are summarised in Table II. This table also
gives details of how sensitive estimates are to alternative
assumptions about the costs of emesis management. High
estimates reflect a doubling of all cost assumptions (i.e. cost
of responding to emesis of £60 rather than £30) and low
estimates a halving of these assumptions.
Discussion
The results of these cost and cost-effectiveness analyses sug-
gest that, given the therapeutic superiority of ondansetron in
the avoidance of chemotherapy-induced emesis, ondansetron
could be priced considerably higher than metoclopramide
and still offer lower or equal net treatment costs, and at a
still higher price ratio can offer lower or equal cost per unit
of effect. This analysis provides preliminary estimates of these
ratios and confirms that this approach offers a useful tool for
pre-marketing economic evaluation.
The present estimates of the magnitude of the differences
in net treatment costs, at various drug price levels, are sen-
sitive to assumptions made about the costs of managing
emetic episodes and treatment side-effects. The study used
crude estimates, but empirical data are now being collected in
a number of countries to cost more accurately emesis and
associated effects. Additionally it would be important and
Table II Drug price ratios which give (i) net treatment cost equivalence
and (ii) equalise ratios of cost per unit effect
Price-ratios (R*)
(Ondansetron: Metoclopramide)
Base High Low
case costs costs
(i) Cost minimisation: 2.3 3.5 1.6
(ii) Cost-effectiveness:
Cost per success:
no emesis 5.0 8.0 3.3
Cost per success:
no emesis and
no side-effects 5.1 8.2 3.4
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relatively easy to establish whether similar results would be
produced from subsequent trials of ondansetron versus
metoclopramide. Until the necessary trials are undertaken it
would be difficult to establish the extent to which similar
cost-effectiveness ratios hold true when the comparator is not
a single agent, but the common practise of using antiemetics
in combination.
This study does not embody any information about patient
preferences for the avoidance of emesis and/or the side-effects
of antiemetic therapy. Implicit in the definition of success for
the cost-effectiveness analysis is the assumption that the
avoidance of emesis is of equal value to patients as the
avoidance of antiemetic side-effects. A more comprehensive
study design would be cost-utility analysis where patient
preferences would be elicited concerning the relative desir-
ability of the various therapeutic pathways.
An interesting extension of the cost-effectiveness analysis
would be to extend the focus of the study. Although patients
may not view emesis as being the worst of all chemotherapy
side-effects, some clinicians have argued that a bad emetic
experience may reduce a patient's willingness to complete a
sequence of therapies (Smyth, 1988). If longitudinal data
were available on the relationship between non-completion
due to emesis and long term survival then it might be possi-
ble to undertake cost-effectiveness analysis with deaths
averted or life-years gained as the measure of effect.
This work was undertaken with financial support from Glaxo
Holdings, and the authors thank Nick Wells for his helpful com-
ments on earlier drafts.
Notes
(1) Hallet (1988) suggests that 'with each episode of
vomiting the nurse must immediately supply a clean recep-
tacle, a tooth brush and a mouthwash, a bowl for washing
and often a change of bed linen and nightwear. Sometimes it
is necessary to actually physically support a weak and
drowsy patient. Protracted vomiting is in itself exhausting
and may leave the patient dependent upon the nurse for help
with all physical activities'.
(2) The detailed cost assumption are as follows:
Additional cost of dealing with emesis (per patient with
significant emesis): £
2 h of nursing time 10
Linen, disposables etc 5
20 min of junior doctor's time 3
0.1 probability of additional day's stay 12
Total 30
Additional cost of dealing with side-effects (per patient with
significant side-effects): £
1 h of nursing time 5
20 min of junior doctor's time 3
0.1 probability of additional day's stay 12
Total 20
Additional cost of treating side-effects (per patient who
receives treatment): £
20min of junior doctor's time 3
Drug costs 2
Total 5
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